ReviewCurrent osteoporosis reports2012
Inhibition of cathepsin K for treatment of osteoporosis.
Review in Current osteoporosis reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Tai chi for treating osteopenia and primary osteoporosis: a meta-analysis and trial sequential analysis.Clinical interventions in aging · 2019Pooled it
- Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice.Drug design, development and therapy · 2017Pooled it
- Modern Strategies for Osteoporosis Therapy: Current Status and Prospects for Targeted Intervention.International journal of molecular sciences · 2025Review
- Cathepsin K-Activated Probe for Fluoro-Photoacoustic Imaging of Early Osteolytic Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Cathepsin K inhibition induces Raptor destabilization and mitochondrial dysfunction via Syk/SHP2/Src/OTUB1 axis-mediated signaling.Cell death & disease · 2023Article
- Clinicopathological correlation of Cathepsin K expression in salivary gland carcinomas; relation to patients` outcome.Diagnostic pathology · 2023Article
- Cathepsin K: A Versatile Potential Biomarker and Therapeutic Target for Various Cancers.Current oncology (Toronto, Ont.) · 2022Review
- The Pathophysiology of Osteoporosis after Spinal Cord Injury.International journal of molecular sciences · 2021Review
- The Role of Cysteine Peptidases in Hematopoietic Stem Cell Differentiation and Modulation of Immune System Function.Frontiers in immunology · 2021Review
- Osteoporosis: Pathophysiology and therapeutic options.EXCLI journal · 2020Review
- Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.British journal of clinical pharmacology · 2019Review
- LRRK1 regulation of actin assembly in osteoclasts involves serine 5 phosphorylation of L-plastin.Journal of cellular biochemistry · 2018Article
- Optimized Extract fromEvidence-based complementary and alternative medicine : eCAM · 2018Article
- Protocatechuic Acid Attenuates Trabecular Bone Loss in Ovariectomized Mice.Oxidative medicine and cellular longevity · 2018Article
- Pycnodysostosis with novel gene mutation and sporadic medullary thyroid carcinoma: A case report.Medicine · 2017Article
- Targeting subchondral bone mesenchymal stem cell activities for intrinsic joint repair in osteoarthritis.Future science OA · 2017Review
- Discovery of a New Class of Cathepsin K Inhibitors in Rhizoma Drynariae as Potential Candidates for the Treatment of Osteoporosis.International journal of molecular sciences · 2016Article
- From disease to treatment: from rare skeletal disorders to treatments for osteoporosis.Endocrine · 2016Review
- Orthopedic tissue regeneration: cells, scaffolds, and small molecules.Drug delivery and translational research · 2016Review
- Enhanced osteoclastogenesis by mitochondrial retrograde signaling through transcriptional activation of the cathepsin K gene.Annals of the New York Academy of Sciences · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cathepsin K is the protease that is primarily responsible for the degradation of bone matrix by osteoclasts. Inhibitors of cathepsin K are in development for treatment of osteoporosis. Currently available antiresorptive drugs interfere with osteoclast function. They inhibit both bone resorption and formation, due to the coupling between these processes. Cathepsin K inhibitors, conversely, target the resorption process itself and may not interfere with osteoclast stimulation of bone formation. In fact, when cathepsin K is absent or inhibited in mice, rabbits, or monkeys, bone formation is maintained or increased. In humans, inhibition of cathepsin K is associated with sustained reductions in bone resorption markers but with smaller and transient reductions in bone formation markers. The usefulness of cathepsin K inhibitors in osteoporosis is now being examined in phase 2 and phase 3 clinical trials of postmenopausal osteoporotic women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.